The FDA has approved Dupixent for the treatment of chronic obstructive pulmonary disease, expanding its use beyond immune-mediated diseases. The drug has shown to be effective in reducing flare-ups and improving breathing in COPD patients, specifically those with uncontrolled symptoms driven by eosinophils. This approval gives Dupixent an edge over rival treatments and opens up treatment options for the estimated 300,000 eligible patients in the U.S. The drug, developed by Regeneron and Sanofi, has shown to be safe and well-tolerated in late-stage trials, solidifying its status as a potentially groundbreaking therapy for COPD.
Source link
Blockbuster Dupixent wins FDA approval for COPD
